Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more
Bolt Biotherapeutics - Asset Resilience Ratio
Bolt Biotherapeutics (BOLT) has an Asset Resilience Ratio of 21.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Bolt Biotherapeutics's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Bolt Biotherapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.16 Million | 21.76% |
| Total Liquid Assets | $14.16 Million | 21.76% |
Asset Resilience Insights
- Good Liquidity Position: Bolt Biotherapeutics maintains a healthy 21.76% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Bolt Biotherapeutics Industry Peers by Asset Resilience Ratio
Compare Bolt Biotherapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Bolt Biotherapeutics (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Bolt Biotherapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 40.27% | $40.12 Million | $99.63 Million | -16.92pp |
| 2023-12-31 | 57.19% | $91.38 Million | $159.78 Million | -12.89pp |
| 2022-12-31 | 70.08% | $159.64 Million | $227.81 Million | +18.46pp |
| 2021-12-31 | 51.62% | $158.84 Million | $307.72 Million | +14.46pp |
| 2020-12-31 | 37.16% | $17.30 Million | $46.54 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $48.45 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $15.97 Million | -- |